Drug delivery at the aortic valve tissues of healthy domestic pigs with a Paclitaxel-eluting valvuloplasty balloon

J Interv Cardiol. 2009 Jun;22(3):291-8. doi: 10.1111/j.1540-8183.2009.00447.x. Epub 2009 May 13.

Abstract

Background: Restenosis occurs invariably within 1 year following balloon valvulopasty in aortic valve stenosis. The mechanism of restenosis seems to involve a dynamic cellular component that could be a target for drug inhibition. We investigated the feasibility of local drug delivery at the aortic valve tissues of healthy pigs with a paclitaxel-eluting balloon.

Methods: Aortic valvuloplasty was performed in eight anesthetized domestic pigs using paclitaxel-eluting balloons (3 micro2) balloon surface area). They were assigned to two or four times 15-second balloon inflations and were sacrificed 30 minutes after final balloon inflation.

Results: The aortic annulus to balloon diameter ratio was 1.15 +/- 0.07. The mean paclitaxel concentration in the aortic valve leaflets was 0.91 +/- 1.36 micro (0.34 +/- 0.05 micro in the two-inflation group, 1.48 +/- 1.86 micro in the four-inflation group, P = 0.23). The percentage of the total paclitaxel dose recovered in the aortic valve leaflets was 18 +/- 11(-6)% (13 +/- 6(-6)% and 25 +/- 14(-6)% in the two- and four-inflation group, P = 0.16).

Conclusion: Local drug delivery at the aortic valve leaflets of healthy pigs with a paclitaxel-eluting balloon is feasible and concentrations within the therapeutic window are detected 30 minutes after the procedure. The antirestenotic potential of this treatment should be studied.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents, Phytogenic / administration & dosage
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Aortic Valve / drug effects*
  • Aortic Valve / pathology
  • Aortic Valve / surgery
  • Catheterization*
  • Drug Delivery Systems
  • Drug-Eluting Stents*
  • Feasibility Studies
  • Paclitaxel / administration & dosage
  • Paclitaxel / therapeutic use*
  • Swine

Substances

  • Antineoplastic Agents, Phytogenic
  • Paclitaxel